{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:55:22Z","timestamp":1793249722178,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":2531,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T00:00:00Z","timestamp":1548720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Doxorubicin (DOX) can cause cumulative cardiotoxicity in dogs, but the incidence of clinical cardiotoxicity in dogs receiving DOX has not been determined.<\/jats:p>\n <\/jats:sec>\n \n Hypothesis\/Objectives<\/jats:title>\n To determine if the duration of DOX infusion influences the incidence of cardiotoxicity, to characterize the incidence of clinical cardiotoxicity in dogs during or after DOX chemotherapy, and to identify any risk factors associated with cardiotoxicity.<\/jats:p>\n <\/jats:sec>\n \n Animals<\/jats:title>\n Four-hundred ninety-four dogs that received at least 1 dose of DOX for the treatment of cancer.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Retrospective study of dogs that received DOX from 2006 to 2015.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 494 dogs, 20 (4.0%) developed clinical cardiotoxicity. The duration of DOX infusion was not significantly associated with clinical cardiotoxicity, whereas a higher cumulative dose of DOX, higher body weight, decreases in fractional shortening after 5 doses of DOX, and development of ventricular premature contractions were significantly associated with clinical cardiotoxicity. High-risk breeds for developing dilated cardiomyopathy had an incidence of 15.4%, whereas low-risk breeds had an incidence of 3.0%.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Clinical Importance<\/jats:title>\n Although the duration of DOX infusion did not influence the incidence of cardiotoxicity, premature contractions and decreases in fractional shortening should raise concern for the development of clinical cardiotoxicity. Overall, the incidence of clinical DOX-induced cardiotoxicity is low, but Boxers and other breeds at high risk for dilated cardiomyopathy may be at an increased risk.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/jvim.15414","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T02:49:12Z","timestamp":1548816552000},"page":"783-791","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Incidence and risk factors associated with development of clinical cardiotoxicity in dogs receiving doxorubicin"],"prefix":"10.1093","volume":"33","author":[{"given":"Briana E.","family":"Hallman","sequence":"first","affiliation":[{"name":"North Carolina State University, College of Veterinary Medicine Department of Clinical Sciences, , Raleigh, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene L.","family":"Hauck","sequence":"additional","affiliation":[{"name":"North Carolina State University, College of Veterinary Medicine Department of Clinical Sciences, , Raleigh, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel E.","family":"Williams","sequence":"additional","affiliation":[{"name":"Veterinary Specialty Hospital of the Carolinas , Cary, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Hess","sequence":"additional","affiliation":[{"name":"North Carolina State University, College of Veterinary Medicine Department of Clinical Sciences, , Raleigh, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4972-3571","authenticated-orcid":false,"given":"Steven E.","family":"Suter","sequence":"additional","affiliation":[{"name":"North Carolina State University, College of Veterinary Medicine Department of Clinical Sciences, , Raleigh, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,1]]},"reference":[{"key":"2026020922233627200_jvim15414-bib-0001","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/02656739209021774","article-title":"Phase III evaluation of doxorubicin and whole-body hyperthermia in dogs with lymphoma","volume":"8","author":"Page","year":"1992","journal-title":"Int J Hyperthermia"},{"key":"2026020922233627200_jvim15414-bib-0002","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2460\/javma.1983.182.01.70","article-title":"Doxorubicin therapy in the dog","volume":"182","author":"Susaneck","year":"1983","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922233627200_jvim15414-bib-0003","first-page":"865","article-title":"Anthracycline cardiomyopathy monitored by morphologic changes","volume":"62","author":"Billingham","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"2026020922233627200_jvim15414-bib-0004","doi-asserted-by":"crossref","first-page":"304","DOI":"10.2460\/javma.240.3.304","article-title":"Dexrazoxane treatment of doxorubicin extravasation injury in four dogs","volume":"240","author":"Venable","year":"2012","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922233627200_jvim15414-bib-0005","first-page":"963","article-title":"Adriamycin-induced cardiac dysrhythmias in an experimental dog model","volume":"62","author":"Kehoe","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"2026020922233627200_jvim15414-bib-0006","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for DOX-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"key":"2026020922233627200_jvim15414-bib-0007","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2","article-title":"A clinicopathologic analysis of Adriamycin cardiotoxicity","volume":"32","author":"Lefrak","year":"1973","journal-title":"Cancer"},{"key":"2026020922233627200_jvim15414-bib-0008","first-page":"68","article-title":"Doxorubicin-induced cardiotoxicity in five dogs","volume":"1","author":"Loar","year":"1986","journal-title":"Sem Vet Med Surg (Small Anim)"},{"key":"2026020922233627200_jvim15414-bib-0009","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1939-1676.1992.tb03156.x","article-title":"Doxorubicin-induced cardiotoxicosis \u2013 clinical features in 32 dogs","volume":"6","author":"Mauldin","year":"1992","journal-title":"J Vet Intern Med"},{"key":"2026020922233627200_jvim15414-bib-0010","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","article-title":"Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities","volume":"64","author":"Vejpongsa","year":"2014","journal-title":"J Amer Coll Cardiol"},{"key":"2026020922233627200_jvim15414-bib-0011","first-page":"1251","article-title":"Clinical Oncology","author":"Abeloff","year":"2004","edition":"3"},{"key":"2026020922233627200_jvim15414-bib-0012","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jama.1976.03270030049033","article-title":"Cardiac effects of doxorubicin therapy of neoplasms","volume":"236","author":"Ugoretz","year":"1976","journal-title":"J Amer Med Assoc"},{"key":"2026020922233627200_jvim15414-bib-0013","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/1097-0142(19850915)56:6<1361::AID-CNCR2820560624>3.0.CO;2-S","article-title":"Doxorubicin-induced congestive heart failure in adults","volume":"56","author":"Haq","year":"1985","journal-title":"Cancer"},{"key":"2026020922233627200_jvim15414-bib-0014","doi-asserted-by":"crossref","first-page":"168","DOI":"10.7326\/0003-4819-88-2-168","article-title":"Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization","volume":"88","author":"Bristow","year":"1978","journal-title":"Ann Int Med"},{"key":"2026020922233627200_jvim15414-bib-0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40169-017-0148-3","article-title":"Anthracycline induced cardiotoxicity: biomarkers and \u201cOmics\u201d technology in the era of patient specific care","volume":"6","author":"Moazeni","year":"2017","journal-title":"Clin Trans Med"},{"key":"2026020922233627200_jvim15414-bib-0016","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-96-2-133","article-title":"Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion","volume":"96","author":"Legha","year":"1982","journal-title":"Ann Intern Med"},{"key":"2026020922233627200_jvim15414-bib-0017","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"2026020922233627200_jvim15414-bib-0018","first-page":"46","article-title":"Effect of a 1-hour IV infusion of doxorubicin on the development of cardiotoxicity in dogs as evaluated by electrocardiography and echocardiography","volume":"10","author":"Gillings","year":"2009","journal-title":"Vet Ther"},{"key":"2026020922233627200_jvim15414-bib-0019","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1760-2734(06)70047-9","article-title":"Proposed guidelines for the diagnosis of canine idiopathic dilated cardiomyopathy","volume":"5","author":"Dukes-McEwen","year":"2003","journal-title":"J Vet Cardiol"},{"key":"2026020922233627200_jvim15414-bib-0020","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1476-5829.2010.00225.x","article-title":"Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient","volume":"8","author":"FitzPatrick","year":"2010","journal-title":"Vet Comp Oncol"},{"key":"2026020922233627200_jvim15414-bib-0021","first-page":"4200","article-title":"Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs","volume":"56","author":"Imondi","year":"1996","journal-title":"Cancer Res"},{"key":"2026020922233627200_jvim15414-bib-0022","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1177\/0300985810377185","article-title":"Sudden death in a dog after doxorubicin chemotherapy","volume":"48","author":"Banco","year":"2011","journal-title":"Vet Pathol"},{"key":"2026020922233627200_jvim15414-bib-0023","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/1097-0142(19900215)65:4<870::AID-CNCR2820650407>3.0.CO;2-D","article-title":"Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen: a prospective randomized evaluation","volume":"65","author":"Shapira","year":"1990","journal-title":"Cancer"},{"key":"2026020922233627200_jvim15414-bib-0024","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1634\/theoncologist.2007-0247","article-title":"Dexrazoxane (Totect\u2122): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy","volume":"13","author":"Kane","year":"2008","journal-title":"Oncologist"},{"key":"2026020922233627200_jvim15414-bib-0025","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy","volume":"339","author":"Singal","year":"1998","journal-title":"New Engl J Med"},{"key":"2026020922233627200_jvim15414-bib-0026","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1365-2796.2001.00820.x","article-title":"Comparison of echocardiography and radionuclide ventriculography in the follow-up of left ventricular systolic function in adult lymphoma patients during doxorubicin therapy","volume":"249","author":"Nousiainen","year":"2001","journal-title":"J Int Med"},{"key":"2026020922233627200_jvim15414-bib-0027","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1476-5810.2004.00051.x","article-title":"Cardiac troponin I in canine patients with lymphoma and osteosarcoma receiving doxorubicin: comparison with clinical heart disease in a retrospective analysis","volume":"2","author":"Selting","year":"2004","journal-title":"Vet Comp Oncol"},{"key":"2026020922233627200_jvim15414-bib-0028","first-page":"89","article-title":"Value of echocardiography and electrocardiography as screening tools prior to doxorubicin administration","volume":"48","author":"Ratterree","year":"2012","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922233627200_jvim15414-bib-0029","first-page":"221","article-title":"Single agent therapy with adriamycin for canine lymphosarcoma","volume":"24","author":"Postorino","year":"1989","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026020922233627200_jvim15414-bib-0030","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.cvsm.2017.04.007","article-title":"Arrhythmogenic right ventricular cardiomyopathy in the Boxer dog: an update","volume":"7","author":"Meurs","year":"2017","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"2026020922233627200_jvim15414-bib-0031","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(19820701)50:1<32::AID-CNCR2820500108>3.0.CO;2-Q","article-title":"Efficacy and cost of cardiac monitoring in patients receiving doxorubicin","volume":"50","author":"Bristow","year":"1982","journal-title":"Cancer"},{"key":"2026020922233627200_jvim15414-bib-0032","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1002\/cam4.813","article-title":"Noninvasive early detection of anthracycline-induced cardiotoxicity in patients with hematologic malignancies using the phased tracking method","volume":"5","author":"Saito","year":"2016","journal-title":"Cancer Med"},{"key":"2026020922233627200_jvim15414-bib-0033","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"2026020922233627200_jvim15414-bib-0034","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s002800100348","article-title":"The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity","volume":"48","author":"Herman","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026020922233627200_jvim15414-bib-0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0009-8981(03)00013-5","article-title":"Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings","volume":"329","author":"Bertinchant","year":"2003","journal-title":"Clin Chim Acta"},{"key":"2026020922233627200_jvim15414-bib-0036","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1939-1676.2002.tb02386.x","article-title":"Prospective clinical evaluation of serum cardiac troponin T in dogs admitted to a veterinary teaching hospital","volume":"16","author":"DeFrancesco","year":"2002","journal-title":"J Vet Intern Med"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.15414","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.15414","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.15414","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/33\/2\/783\/66659787\/jvim15414.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/33\/2\/783\/66659787\/jvim15414.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:37:16Z","timestamp":1770694636000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/33\/2\/783\/8448138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.15414","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2019,3,1]]},"assertion":[{"value":"2018-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}